08.03.2018 13:53:00
|
CosmosID Appoints Arne Materna as Vice President of Product
ROCKVILLE, Md., March 8, 2018 /PRNewswire/ -- CosmosID, provider of leading products and services to unlock the microbiome accurately and actionably, is proud to announce that Dr. Arne Materna is joining its Senior Leadership team as Vice President of Product.
Dr. Materna's experience in product and business strategy in the field of metagenomics and infectious disease genomics will fuel the strategic expansion of the product portfolio and the growth of CosmosID.
Dr. Materna joins CosmosID from QIAGEN where he directed the product management organization responsible for a high-growth segment of QIAGEN's extensive portfolio of bioinformatics products. Prior to QIAGEN Dr. Materna held management and senior roles at CLC bio, Pacific Biosciences and MIT.
In his new role, Dr. Materna will drive product strategy at CosmosID. "We are delighted to welcome Dr. Materna to our leadership team," says Manoj Dadlani, CEO of CosmosID. "Arne's strong understanding of customer needs across the entire NGS workflow, from sample processing through actionable data interpretation, will help drive the best possible products and solutions for our growing customer base."
"I am honored to join the scientifically stellar and ambitious team at CosmosID," said Arne Materna. "Assets like a HIPPA compliant bioinformatics platform and CLIA facilities for end-to-end services uniquely positions CosmosID in providing microbiome solutions for both research and regulated applications."
CosmosID, a Rockville MD based company, is best known for microbial identification and microbiome profiling with unrivaled accuracy and strain level resolution. The class-leading performance of CosmosID bioinformatics is powered by the CosmosID GenBook® database, the largest curated genome database of pathogens, commensals and environmental microorganisms.
"Our technology is deeply rooted in CosmosID's core values, which include a tradition of scientific excellence and extensive collaboration with the scientific community," says Prof. Rita Colwell, founder and chairman of CosmosID. "I am enthusiastic to have Dr. Materna joining our team. He is an accomplished industry leader and an experienced and passionate microbiologist."
Dr. Materna holds a PhD in molecular biology from the University of Konstanz, Germany. His specialization is in microbial ecology and metagenomics. Dr. Materna conducted his postdoctoral research at MIT, where he subsequently directed the experimental research laboratory of Prof. Eric Alm. At QIAGEN, Dr. Materna launched a successful software platform for microbial surveillance and metagenomics that has had broad adoption in commercial laboratories and government agencies including the FDA, CDC and USDA. He also serves as Expert Advisor to the ISO Standardization Working Group 25 for Whole Genome Sequencing of Foodborne Pathogens.
About CosmosID
CosmosID®, based in Rockville, Maryland, is a genomics big data company focused on rapid identification of microorganisms for molecular diagnostics, public health, food safety, agriculture, and environmental applications. The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing. To learn more please visit www.cosmosid.com.
Contact:
Jonathan Ryan
703-995-9879
191554@email4pr.com
View original content with multimedia:http://www.prnewswire.com/news-releases/cosmosid-appoints-arne-materna-as-vice-president-of-product-300610666.html
SOURCE CosmosID
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu CoStar Group Inc.mehr Nachrichten
02.01.25 |
S&P 500-Titel CoStar Group-Aktie: So viel Verlust wäre bei einem Investment in CoStar Group von vor einem Jahr angefallen (finanzen.at) | |
26.12.24 |
S&P 500-Papier CoStar Group-Aktie: So viel Gewinn hätte ein CoStar Group-Investment von vor 10 Jahren abgeworfen (finanzen.at) | |
19.12.24 |
S&P 500-Papier CoStar Group-Aktie: So viel Gewinn hätte ein CoStar Group-Investment von vor 5 Jahren abgeworfen (finanzen.at) | |
13.12.24 |
Handel in New York: NASDAQ 100 liegt letztendlich im Plus (finanzen.at) | |
13.12.24 |
Pluszeichen in New York: NASDAQ 100 am Nachmittag fester (finanzen.at) | |
12.12.24 |
S&P 500-Wert CoStar Group-Aktie: Hätte sich eine Investition in CoStar Group von vor 3 Jahren rentiert? (finanzen.at) | |
05.12.24 |
Schwache Performance in New York: NASDAQ 100 präsentiert sich am Mittag leichter (finanzen.at) | |
05.12.24 |
Optimismus in New York: S&P 500 steigt (finanzen.at) |
Analysen zu CoStar Group Inc.mehr Analysen
Aktien in diesem Artikel
CoStar Group Inc. | 70,08 | 1,74% |